COI policies up among med schools

COI policies up among med schools
COI policies up among med schools

For the first time since 2007, over two-thirds of medical schools have “model” conflict-of-interest policies in place, but industry support for CME remains one concern.

That was the finding of the American Medical Students Association (AMSA), which in March released its fifth scorecard of conflict policies among the 152 medical schools in the US and Puerto Rico.

The group's PharmFree Scorecard, which it develops in conjunction with the Pew Prescription Project, found a year-over-year increase in schools with A or B grades to 102, from 79 (52%) in 2010 and 45 (30%) in 2009.

“This demonstrates a new baseline,” the group said in a summary of the results.

About a quarter improved their policies since last year, including Harvard Medical School, which scored an A through a strong policy that includes a ban on speakers' bureaus in addition to strong rules regarding gifts, disclosure and samples.

Financial support for CME, however, remains “challenging,” AMSA said; only 20 schools, up from 15 in 2010, earned perfect scores with respect to on-campus CME; 88, up from 75 in 2010, earned ideal scores with respect to support for off-campus CME.

Among other policies assessed by the ScoreCard are acceptance of consulting and speaking relationships and access of company sales reps to academic or hospital personnel.
You must be a registered member of MMM to post a comment.
close

Next Article in Features


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.